医薬品商業化におけるAI：市場洞察・競合情勢・市場予測 (～2032年)

医薬品商業化におけるAIの市場規模は、予測期間中にCAGR 24.12％で成長すると予測されています。

慢性疾患の有病率の上昇が、革新的で効果的な治療に対する需要を促進し、AI主導の医薬品商業化の必要性を加速させています。リアルワールドエビデンス (RWE) が重視されるようになったことで、製薬会社はAIを個別化医療に活用し、医薬品開発と市場開拓の両方を最適化できるようになっています。さらに、技術プロバイダーと製薬企業との協業の増加により、AIの統合が加速し、データ分析能力が強化され、商品化プロセスが合理化されています。

市場力学：

Global Cancer Observatoryの最新データによると、2022年には世界で推定2,000万件の新規癌症例が記録され、2045年には3,260万件に増加すると予測されています。癌は依然として罹患率と死亡率の主要原因であるため、製薬企業は精密癌治療薬、免疫療法、標的治療薬の開発にますます力を入れるようになっています。AIは、創薬、臨床試験デザイン、患者層別化を強化し、より迅速で効果的な商品化を実現することで、この取り組みにおいて極めて重要な役割を果たしています。AIを活用したリアルワールドエビデンス (RWE) の分析により、製薬企業は治療反応の理解を深め、疾患の進行を予測し、商業化戦略を洗練させることができます。さらに、AIを活用したバイオマーカー解析は、理想的な患者人口の特定に役立ち、癌治療薬の市場参入と採用を改善します。

癌領域以外では、心血管疾患 (CVD) も医薬品の商業化におけるAIの採用を促進しています。World Heart Federation (2024年) によると、2022年には世界で約6,000万人が心房細動に罹患しています。これは最も一般的な不整脈の1つで、血栓、心不全、脳卒中のリスクを高め、心房細動の患者は脳卒中になる可能性が5倍高いとされています。AIは、大規模なデータセットを解析して潜在的な薬剤候補を特定し、開発時間とコストを削減することで、CVDの創薬・再利用プロセスを変革しています。CVDの複雑性を考慮すると、既存の研究、患者記録、臨床試験データをマイニングすることで、AIは製薬会社による新たな治療オプションの発見を可能にするでしょう。

当レポートでは、世界の医薬品商業化におけるAIの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 医薬品商業化におけるAI市場レポート：イントロダクション

第2章 医薬品商業化におけるAI市場：エグゼクティブサマリー

• 市場概要

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 医薬品商業化におけるAI市場：主要要因分析

• 市場促進要因
  • 慢性疾患の増加
  • 個別化医療を推進する上でのリアルワールドエビデンス (RWE) の重要性の高まり
  • AIを活用した医薬品の商業化を推進するための技術企業と製薬会社間の連携の拡大
• 市場抑制要因と課題
  • プライバシーとデータ漏洩の懸念
  • 理解不足や失業の恐れによるAIツール導入への抵抗
• 市場機会
  • 新興市場におけるAI主導の医薬品商業化戦略の導入

第6章 医薬品商業化におけるAI市場：ポーターのファイブフォース分析

第7章 医薬品商業化におけるAI市場：市場の評価

• サービスタイプ別
  • 規制および法務サービス
  • 市場アクセスと価格設定
  • マーケティングとブランディング
  • その他
• 薬剤タイプ別
  • 小分子
  • 生物学的製剤
• 商業化段階別
  • 発売前
  • 発売時
  • 発売後
• 適応症別
  • 腫瘍
  • 心臓血管
  • 神経学
  • 感染症
• エンドユーザー別
  • 製薬・バイオテクノロジー企業
  • CRO
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 医薬品商業化におけるAI市場：企業と製品のプロファイル

• EVERSANA
• Lyfegen
• Syneos Health
• McKinsey & Company
• ICON plc.
• Clarivate
• Thermo Fisher Scientific Inc.
• Viseven
• ZS Associates
• Cloud Pharmaceuticals Inc.

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Artificial Intelligence in Drug Commercialization Market in Global (2022-2032)
• Table 3: Artificial Intelligence in Drug Commercialization Market in Global by Service Type (2022-2032)
• Table 4: Artificial Intelligence in Drug Commercialization Market in Global by Drug Type (2022-2032)
• Table 5: Artificial Intelligence in Drug Commercialization Market in Global by Commercialization Stage (2022-2032)
• Table 6: Artificial Intelligence in Drug Commercialization Market in Global by Indication(2022-2032)
• Table 7: Artificial Intelligence in Drug Commercialization Market in Global by End-User (2022-2032)
• Table 8: Artificial Intelligence in Drug Commercialization Market in Global by Geography (2022-2032)
• Table 9: Artificial Intelligence in Drug Commercialization Market in North America (2022-2032)
• Table 10: Artificial Intelligence in Drug Commercialization Market in the United States (2022-2032)
• Table 11: Artificial Intelligence in Drug Commercialization Market in Canada (2022-2032)
• Table 12: Artificial Intelligence in Drug Commercialization Market in Mexico (2022-2032)
• Table 13: Artificial Intelligence in Drug Commercialization Market in Europe (2022-2032)
• Table 14: Artificial Intelligence in Drug Commercialization Market in France (2022-2032)
• Table 15: Artificial Intelligence in Drug Commercialization Market in Germany (2022-2032)
• Table 16: Artificial Intelligence in Drug Commercialization Market in United Kingdom (2022-2032)
• Table 17: Artificial Intelligence in Drug Commercialization Market in Italy (2022-2032)
• Table 18: Artificial Intelligence in Drug Commercialization Market in Spain (2022-2032)
• Table 19: Artificial Intelligence in Drug Commercialization Market in the Rest of Europe (2022-2032)
• Table 20: Artificial Intelligence in Drug Commercialization Market in Asia-Pacific (2022-2032)
• Table 21: Artificial Intelligence in Drug Commercialization Market in China (2022-2032)
• Table 22: Artificial Intelligence in Drug Commercialization Market in Japan (2022-2032)
• Table 23: Artificial Intelligence in Drug Commercialization Market in India (2022-2032)
• Table 24: Artificial Intelligence in Drug Commercialization Market in Australia (2022-2032)
• Table 25: Artificial Intelligence in Drug Commercialization Market in South Korea (2022-2032)
• Table 26: Artificial Intelligence in Drug Commercialization Market in Rest of Asia-Pacific (2022-2032)
• Table 27: Artificial Intelligence in Drug Commercialization Market in the Rest of the World (2022-2032)
• Table 28: Artificial Intelligence in Drug Commercialization Market in the Middle East (2022-2032)
• Table 29: Artificial Intelligence in Drug Commercialization Market in Africa (2022-2032)
• Table 30: Artificial Intelligence in Drug Commercialization Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Artificial Intelligence in Drug Commercialization Market in Global (2022-2032)
• Figure 3: Artificial Intelligence in Drug Commercialization Market in Global by Service Type (2022-2032)
• Figure 4: Artificial Intelligence in Drug Commercialization Market in Global by Drug Type (2022-2032)
• Figure 5: Artificial Intelligence in Drug Commercialization Market in Global by Commercialization Stage (2022-2032)
• Figure 6: Artificial Intelligence in Drug Commercialization Market in Global by Indication(2022-2032)
• Figure 7: Artificial Intelligence in Drug Commercialization Market in Global by End-User (2022-2032)
• Figure 8: Artificial Intelligence in Drug Commercialization Market in Global by Geography (2022-2032)
• Figure 9: Artificial Intelligence in Drug Commercialization Market in North America (2022-2032)
• Figure 10: Artificial Intelligence in Drug Commercialization Market in the United States (2022-2032)
• Figure 11: Artificial Intelligence in Drug Commercialization Market in Canada (2022-2032)
• Figure 12: Artificial Intelligence in Drug Commercialization Market in Mexico (2022-2032)
• Figure 13: Artificial Intelligence in Drug Commercialization Market in Europe (2022-2032)
• Figure 14: Artificial Intelligence in Drug Commercialization Market in France (2022-2032)
• Figure 15: Artificial Intelligence in Drug Commercialization Market in Germany (2022-2032)
• Figure 16: Artificial Intelligence in Drug Commercialization Market in United Kingdom (2022-2032)
• Figure 17: Artificial Intelligence in Drug Commercialization Market in Italy (2022-2032)
• Figure 18: Artificial Intelligence in Drug Commercialization Market in Spain (2022-2032)
• Figure 19: Artificial Intelligence in Drug Commercialization Market in the Rest of Europe (2022-2032)
• Figure 20: Artificial Intelligence in Drug Commercialization Market in Asia-Pacific (2022-2032)
• Figure 21: Artificial Intelligence in Drug Commercialization Market in China (2022-2032)
• Figure 22: Artificial Intelligence in Drug Commercialization Market in Japan (2022-2032)
• Figure 23: Artificial Intelligence in Drug Commercialization Market in India (2022-2032)
• Figure 24: Artificial Intelligence in Drug Commercialization Market in Australia (2022-2032)
• Figure 25: Artificial Intelligence in Drug Commercialization Market in South Korea (2022-2032)
• Figure 26: Artificial Intelligence in Drug Commercialization Market in Rest of Asia-Pacific (2022-2032)
• Figure 27: Artificial Intelligence in Drug Commercialization Market in the Rest of the World (2022-2032)
• Figure 28: Artificial Intelligence in Drug Commercialization Market in the Middle East (2022-2032)
• Figure 29: Artificial Intelligence in Drug Commercialization Market in Africa (2022-2032)
• Figure 30: Artificial Intelligence in Drug Commercialization Market in South America (2022-2032)
• Figure 31: Market Drivers
• Figure 32: Market Barriers
• Figure 33: Market Opportunities
• Figure 34: PORTER'S Five Force Analysis

Artificial Intelligence (AI) in Drug Commercialization Market by Service Type (Regulatory and Legal Services, Market Access and Pricing, Marketing and Branding, and Others), Drug Type (Small Molecules and Biologics), Commercialization Stage (Pre-launch, Launch, and Post-launch), Indication (Oncology, Cardiovascular, Neurology, Infectious Disease, and Others), End-User (Pharma and Biotech Companies, Contract Research Organizations (CROs), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, the growing importance of Real-World Evidence (RWE) in driving personalized medicine, and growing collaborations among technology companies and pharmaceutical firms to advance AI-driven drug commercialization.

The artificial intelligence in drug commercialization market is estimated to grow at a CAGR of 24.12% during the forecast period from 2025 to 2032. The rising prevalence of chronic diseases is driving demand for innovative and effective treatments, fueling the need for AI-driven drug commercialization. The growing emphasis on Real-World Evidence (RWE) enables pharmaceutical companies to harness AI for personalized medicine, optimizing both drug development and market positioning. Additionally, increasing collaborations between technology providers and pharmaceutical firms are accelerating AI integration, enhancing data analytics capabilities, and streamlining commercialization processes.

Collectively, these factors are propelling the AI-driven drug commercialization market by improving decision-making, reducing costs, and expediting drug approvals, ultimately leading to more efficient and targeted healthcare solutions. As a result, the market is expected to witness significant growth during the forecast period from 2025 to 2032.

Artificial Intelligence in Drug Commercialization Market Dynamics:

According to the latest data from the Global Cancer Observatory, an estimated 20 million new cancer cases were recorded globally in 2022, with projections rising to 32.6 million cases by 2045. As cancer remains a leading cause of morbidity and mortality, pharmaceutical companies are increasingly focusing on developing precision oncology drugs, immunotherapies, and targeted treatments. Artificial Intelligence (AI) plays a pivotal role in this effort by enhancing drug discovery, clinical trial design, and patient stratification, ensuring faster and more effective commercialization. AI-driven analysis of Real-World Evidence (RWE) enables pharmaceutical firms to better understand treatment responses, predict disease progression, and refine commercialization strategies. Additionally, AI-powered biomarker analysis helps identify ideal patient populations, improving market access and adoption of cancer therapies.

Beyond oncology, cardiovascular diseases (CVDs) are also driving AI adoption in drug commercialization. According to the World Heart Federation (2024), approximately 60 million people worldwide were affected by atrial fibrillation in 2022, one of the most common forms of arrhythmia, which increases the risk of blood clots, heart failure, and stroke. Individuals with atrial fibrillation are five times more likely to suffer a stroke. AI is transforming the drug discovery and repurposing process for CVDs by analyzing large datasets to identify potential drug candidates, reducing development time and costs. Given the complexity of CVDs, AI enables pharmaceutical companies to uncover novel treatment options by mining existing research, patient records, and clinical trial data.

Moreover, AI is playing a critical role in optimizing drug pricing models by analyzing extensive datasets to identify trends and support value-based pricing structures that benefit both pharmaceutical companies and healthcare systems. By leveraging AI, companies can streamline reimbursement processes, improve patient access to innovative therapies, and enhance decision-making throughout drug commercialization. AI-driven analytics also assist firms in predicting market demand, assessing competitive landscapes, and refining launch strategies, ultimately reducing costs and expediting time-to-market for new therapies.

For instance, in January 2025, Lyfegen, a global innovator in drug market access, pricing, and rebate management, announced a transformative collaboration with EVERSANA, a leading provider of global commercial services to the life sciences industry. This partnership aims to revolutionize drug pricing and access through AI-driven insights, underscoring the technology's growing influence in the pharmaceutical landscape.

These factors collectively are expected to propel the global AI in drug commercialization market during the forecast period from 2025 to 2032 by improving efficiency, reducing costs, and enhancing patient access to innovative treatments.

However, challenges remain. Privacy and data security concerns, along with resistance to AI adoption stemming from a lack of understanding or fears of job displacement, may pose obstacles to market growth.

Artificial Intelligence in Drug Commercialization Market Segment Analysis:

Artificial Intelligence in Drug Commercialization Market by Service Type (Regulatory and Legal Services, Market Access and Pricing, Marketing and Branding, and Others), Drug Type (Small Molecules and Biologics), Commercialization Stage (Pre-launch, Launch, and Post-launch), Indication (Oncology, Cardiovascular, Neurology, Infectious Disease, and Others), End-User (Pharma and Biotech Companies, Contract Research Organizations (CROs), and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug type segment of artificial intelligence (AI) in drug commercialization market, the small molecules category is expected to hold a significant share in 2024. Small molecules, characterized by their simple chemical structures and low molecular weight, have long been the backbone of pharmaceutical development, comprising the majority of approved drugs for a range of conditions, including infectious diseases, cancer, diabetes, and hypertension. Their versatility and oral bioavailability make them crucial in treating both acute and chronic diseases.

AI is playing an increasingly vital role in optimizing the commercialization of small molecule drugs by enhancing key processes:

1. Accelerated Drug Discovery & Development:

AI-powered algorithms can analyze vast datasets to identify promising small molecule candidates with greater speed and precision than traditional methods. This significantly shortens the preclinical and clinical development phases, allowing new therapies to reach the market faster.

2. Optimized Market Strategies:

AI facilitates the forecasting of market demand, price optimization, and market segmentation by leveraging big data and predictive analytics. This ensures that pharmaceutical companies can better identify optimal markets for commercialization and set competitive pricing strategies.

3. Enhanced Supply Chain Management:

AI-driven tools help anticipate and mitigate supply chain disruptions, ensuring that small molecule drugs are delivered to the right markets and patients efficiently.

4. Personalized Marketing Approaches:

AI enables targeted outreach to healthcare professionals and patients through data-driven marketing strategies. This personalized approach aids in raising awareness and boosting adoption rates of small molecule therapies across diverse regions.

As AI technology continues to evolve, its integration into drug commercialization processes is expected to deepen, helping pharmaceutical companies streamline operations, improve patient outcomes, and enhance market competitiveness.

Thus, these factors collectively are expected to drive growth in the small molecules segment, thereby boosting the overall artificial intelligence in drug commercialization market globally during the forecast period.

North America is expected to dominate the overall artificial intelligence in drug commercialization market:

North America is expected to hold the largest share of artificial intelligence (AI) in drug commercialization market in 2024. This dominance is attributed to the region's robust biotechnology and pharmaceutical industries, advanced healthcare infrastructure, and significant investments in AI research and development. The high prevalence of chronic diseases further drives the demand for AI-driven drug commercialization solutions.

According to GLOBOCAN (2022), North America reported approximately 2.67 million new cancer cases, with projections indicating a rise to 3.83 million by 2045. AI-powered platforms leverage genomic profiles and Real-World Evidence (RWE) from regional patient data to optimize drug discovery, pricing models, and regulatory processes. The region's strong healthcare ecosystem and ongoing collaborations between pharmaceutical companies and AI developers are accelerating commercialization timelines.

AI's integration into precision medicine is particularly impactful in oncology, enabling the identification of biomarkers, patient stratification, and the development of targeted therapies that improve treatment efficacy and accessibility. The synergy between the rising cancer burden and AI's capabilities has established a strong growth trajectory for the market.

Further reflecting this trend, in March 2024, Tonix Pharmaceuticals Holding Corp. partnered with EVERSANA(R), a leading provider of global commercialization services, to support the launch strategy and commercial planning for Tonmya(TM) (TNX-102 SL), a drug under development for fibromyalgia in the U.S. market. This collaboration highlights the increasing reliance on AI-driven strategies in pharmaceutical commercialization, enhancing efficiency, patient targeting, and overall market success.

Thus, all these factors are expected to propel the growth of the artificial intelligence in drug commercialization market in North America during the forecast period from 2025 to 2032.

Artificial Intelligence in Drug Commercialization Market Key Players:

Some of the key market players operating in the artificial intelligence in drug commercialization market include EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., and others.

Recent Developmental Activities in the Artificial Intelligence in Drug Commercialization Market:

• In October 2024, RTI Health Solutions (RTIHS) and Global Pricing Innovations (GPI) announced a strategic collaboration to enhance decision-making and support in drug commercialization. They integrated data seamlessly from clinical development to post-launch, enabling robust insights and optimized market access strategies. By leveraging advanced analytics, they facilitated rapid, data-driven decisions. Their expertise in market access, pricing, and regulatory navigation improved execution speed, HTA submissions, and reimbursement strategies, ensuring successful drug commercialization.
• In July 2024, IntegriChain announced the acquisition of Federal Compliance Solutions (FCS), strengthening its expertise in government pricing and payer/provider contracting amid increasing Pharma outsourcing and regulatory changes. This combination enhanced their technology, personnel, and processes to support more profitable drug commercialization strategies, improve daily business decision-making, and optimize net revenue controls amid growing price concessions.

Key Takeaways From the Artificial Intelligence in Drug Commercialization Market Report Study

• Market size analysis for current artificial intelligence in drug commercialization size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating artificial intelligence in drug commercialization market.
• Various opportunities available for the other competitors in the artificial intelligence in drug commercialization market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current artificial intelligence in drug commercialization market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for artificial intelligence in drug commercialization market growth in the coming future?

Target Audience Who Can Benefited From This Artificial Intelligence in Drug Commercialization Market Report Study

• Artificial intelligence in drug commercialization product providers
• Research organizations and consulting companies
• Artificial intelligence in drug commercialization -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in artificial intelligence in drug commercialization
• Various end-users who want to know more about artificial intelligence in drug commercialization market and the latest technological developments in the artificial intelligence in drug commercialization market.

Frequently Asked Questions for the Artificial Intelligence in Drug Commercialization Market:

1. What is artificial intelligence in drug commercialization?

• Artificial intelligence in drug commercialization refers to the use of advanced AI technologies, such as machine learning, natural language processing, and predictive analytics, to accelerate and optimize drug commercialization. Drug commercialization, enhances marketing strategies, pricing models, real-world evidence generation, and patient engagement, ultimately improving drug accessibility, efficacy, and market success.

2. What is the market for artificial intelligence in drug commercialization?

• The artificial intelligence in drug commercialization market is estimated to grow at a CAGR of 24.12% during the forecast period from 2025 to 2032.

3. What are the drivers for the global artificial intelligence in drug commercialization market?

• The increasing prevalence of chronic diseases is driving demand for innovative and effective treatments, fueling the need for AI-driven drug commercialization. The growing importance of Real-World Evidence (RWE) enables pharmaceutical firms to leverage AI for personalized medicine, optimizing drug development and market positioning. Additionally, rising collaborations between technology companies and pharmaceutical firms are accelerating AI integration, enhancing data analytics, and streamlining commercialization processes. Collectively, these factors are propelling the AI-driven drug commercialization market by improving decision-making, reducing costs, and expediting drug approvals, ultimately leading to more efficient and targeted healthcare solutions. Thus, all the factors mentioned above collectively contribute to the positive growth of artificial intelligence in drug commercialization market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global artificial intelligence in drug commercialization market?

• Some of the key market players operating in artificial intelligence in drug commercialization are EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., and others.

5. Which region has the highest share in the global artificial intelligence in drug commercialization market?

• North America is expected to account for the highest proportion of artificial intelligence in drug commercialization market in 2024, out of all regions. This is due to its strong presence in the biotechnology and pharmaceutical industries. Additionally, high prevalence of chronic diseases, advanced healthcare infrastructure, and significant investment in AI research and development are further boosting the market growth.

Table of Contents

1. Artificial Intelligence in Drug Commercialization Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Artificial Intelligence in Drug Commercialization Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Artificial Intelligence in Drug Commercialization Market Key Factors Analysis

• 5.1. Artificial Intelligence in Drug Commercialization Market Drivers
  • 5.1.1. Increasing prevalence of chronic diseases
  • 5.1.2. The growing importance of Real-World Evidence (RWE) in driving personalized medicine
  • 5.1.3. Growing collaborations among technology companies and pharmaceutical firms to advance AI-driven drug commercialization.
• 5.2. Artificial Intelligence in Drug Commercialization Market Restraints and Challenges
  • 5.2.1. Privacy and data breaching concerns
  • 5.2.2. Resistance to adopting AI tools due to lack of understanding or fear of job displacement
• 5.3. Artificial Intelligence in Drug Commercialization Market Opportunities
  • 5.3.1. Adoption of AI-driven drug commercialization strategies in emerging markets

6. Artificial Intelligence in Drug Commercialization Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Artificial Intelligence in Drug Commercialization Market Assessment

• 7.1. By Service Type
  • 7.1.1. Regulatory and Legal Services
  • 7.1.2. Market Access and Pricing
  • 7.1.3. Marketing and Branding
  • 7.1.4. Others
• 7.2. By Drug Type
  • 7.2.1. Small Molecules
  • 7.2.2. Biologics
• 7.3. By Commercialization Stage
  • 7.3.1. Pre-launch
  • 7.3.2. Launch
  • 7.3.3. Post-launch
• 7.4. By Indication
  • 7.4.1. Oncology
  • 7.4.2. Cardiovascular
  • 7.4.3. Neurology
  • 7.4.4. Infectious Disease
  • 7.4.5. Others
• 7.5. By End-User
  • 7.5.1. Pharma and Biotech Companies
  • 7.5.2. Contract Research Organizations (CROs)
  • 7.5.3. Others
• 7.6. By Geography
  • 7.6.1. North America
    • 7.6.1.1. United States Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.1.2. Canada Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.1.3. Mexico Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
  • 7.6.2. Europe
    • 7.6.2.1. France Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.2.2. Germany Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.2.3. United Kingdom Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.2.4. Italy Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.2.5. Spain Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.2.6. Rest of Europe Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
  • 7.6.3. Asia-Pacific
    • 7.6.3.1. China Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.3.2. Japan Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.3.3. India Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.3.4. Australia Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.3.5. South Korea Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.3.6. Rest of Asia-Pacific Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
  • 7.6.4. Rest of the World (RoW)
    • 7.6.4.1. Middle East Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.4.2. Africa Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)
    • 7.6.4.3. South America Artificial Intelligence in Drug Commercialization Market Size in USD Million (2022-2032)

8. Artificial Intelligence in Drug Commercialization Market Company and Product Profiles

• 8.1. EVERSANA
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Lyfegen
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Syneos Health
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. McKinsey & Company
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. ICON plc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Clarivate
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Thermo Fisher Scientific Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Viseven
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. ZS Associates
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Cloud Pharmaceuticals Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us